Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Optimal approach to first-line therapy in myelofibrosis

Francesco Passamonti • 11 Jun 2022
EHA 2022
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Ruxolitinib

Francesco Passamonti, MD, University of Insubria, Varese, Italy, discusses the first-line treatment of myelofibrosis (MF), commenting on the use of hematopoietic stem cell transplantation (HSCT) and JAK inhibitors like ruxolitinib and fedratinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Francesco Passamonti

1:19
The current state-of-the-art in PV and future outlooks
Francesco Passamonti • 7 Sep 2023
1:00
Current and emerging treatment options for anemia in MF
Francesco Passamonti • 7 Sep 2023
1:13
Results from the ACE‐536‐MF‐001 study
Francesco Passamonti • 7 Sep 2023
1:14
Modern prognostication in MPNs: improving risk stratification & treatment approaches
Francesco Passamonti • 7 Sep 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals